1. Home
  2. ESQ vs OMER Comparison

ESQ vs OMER Comparison

Compare ESQ & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ESQ
  • OMER
  • Stock Information
  • Founded
  • ESQ 2006
  • OMER 1994
  • Country
  • ESQ United States
  • OMER United States
  • Employees
  • ESQ N/A
  • OMER N/A
  • Industry
  • ESQ Commercial Banks
  • OMER Biotechnology: Pharmaceutical Preparations
  • Sector
  • ESQ Finance
  • OMER Health Care
  • Exchange
  • ESQ Nasdaq
  • OMER Nasdaq
  • Market Cap
  • ESQ 756.3M
  • OMER 188.1M
  • IPO Year
  • ESQ 2017
  • OMER 2009
  • Fundamental
  • Price
  • ESQ $96.35
  • OMER $3.65
  • Analyst Decision
  • ESQ Hold
  • OMER Strong Buy
  • Analyst Count
  • ESQ 3
  • OMER 5
  • Target Price
  • ESQ $99.00
  • OMER $18.00
  • AVG Volume (30 Days)
  • ESQ 171.0K
  • OMER 928.7K
  • Earning Date
  • ESQ 07-24-2025
  • OMER 08-06-2025
  • Dividend Yield
  • ESQ 0.73%
  • OMER N/A
  • EPS Growth
  • ESQ 13.51
  • OMER N/A
  • EPS
  • ESQ 5.27
  • OMER N/A
  • Revenue
  • ESQ $124,132,000.00
  • OMER N/A
  • Revenue This Year
  • ESQ N/A
  • OMER N/A
  • Revenue Next Year
  • ESQ $10.72
  • OMER $468.75
  • P/E Ratio
  • ESQ $18.32
  • OMER N/A
  • Revenue Growth
  • ESQ 14.72
  • OMER N/A
  • 52 Week Low
  • ESQ $49.16
  • OMER $2.95
  • 52 Week High
  • ESQ $101.35
  • OMER $13.60
  • Technical
  • Relative Strength Index (RSI)
  • ESQ 56.40
  • OMER 54.74
  • Support Level
  • ESQ $93.57
  • OMER $3.00
  • Resistance Level
  • ESQ $101.28
  • OMER $3.25
  • Average True Range (ATR)
  • ESQ 3.23
  • OMER 0.24
  • MACD
  • ESQ 0.16
  • OMER 0.10
  • Stochastic Oscillator
  • ESQ 58.99
  • OMER 83.33

About ESQ Esquire Financial Holdings Inc.

Esquire Financial Holdings Inc is a financial holding company. Through its subsidiary, the company operates as a full-service commercial bank dedicated to serving the financial needs of the legal industry and small businesses nationally, as well as commercial and retail customers in the New York metropolitan area. The Bank offers tailored products and solutions to the legal community and their clients as well as dynamic and flexible payment processing solutions to small business owners. Banking products offered for businesses and consumers include checking, savings, money market, and time deposits; a wide range of commercial and consumer loans, as well as customary banking services. In addition, it operates a payment processing platform through third-party independent sales organizations.

About OMER Omeros Corporation

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Share on Social Networks: